Seroatlas · Human Serome Atlas

TRAK2

Trafficking kinesin-binding protein 2

Also known as: ALS2CR3, CALS-C, GRIF-1, KIAA0549, MILT2, OIP98, TRAK2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
O60296
Gene
TRAK2
Ensembl
ENSG00000115993
Chromosome
2
Canonical length
914 aa
Protein class
Predicted intracellular proteins
Subcellular location
Nucleoplasm,Nuclear bodies,Vesicles

OverviewNCBI Gene

Predicted to enable GABA receptor binding activity and myosin binding activity. Predicted to be involved in several processes, including mitochondrion distribution; protein O-linked glycosylation; and vesicle transport along microtubule. Predicted to be located in cytoplasm; nucleus; and plasma membrane. Predicted to be active in cytoplasmic vesicle; dendrite; and mitochondrion. [provided by Alliance of Genome Resources, Apr 2025]

Canonical amino-acid sequenceUniProt

914 residues, UniProt reviewed canonical sequence.

>O60296|TRAK2
     1  MSQSQNAIFT SPTGEENLMN SNHRDSESIT DVCSNEDLPE VELVSLLEEQ LPQYRLKVDT
    61  LFLYENQDWT QSPHQRQHAS DALSPVLAEE TFRYMILGTD RVEQMTKTYN DIDMVTHLLA
   121  ERDRDLELAA RIGQALLKRN HVLSEQNESL EEQLGQAFDQ VNQLQHELCK KDELLRIVSI
   181  ASEESETDSS CSTPLRFNES FSLSQGLLQL EMLQEKLKEL EEENMALRSK ACHIKTETVT
   241  YEEKEQQLVS DCVKELRETN AQMSRMTEEL SGKSDELIRY QEELSSLLSQ IVDLQHKLKE
   301  HVIEKEELKL HLQASKDAQR QLTMELHELQ DRNMECLGML HESQEEIKEL RSRSGPTAHL
   361  YFSQSYGAFT GESLAAEIEG TMRKKLSLDE ESSLFKQKAQ QKRVFDTVRI ANDTRGRSIS
   421  FPALLPIPGS NRSSVIMTAK PFESGLQQTE DKSLLNQGSS SEEVAGSSQK MGQPGPSGDS
   481  DLATALHRLS LRRQNYLSEK QFFAEEWQRK IQVLADQKEG VSGCVTPTES LASLCTTQSE
   541  ITDLSSASCL RGFMPEKLQI VKPLEGSQTL YHWQQLAQPN LGTILDPRPG VITKGFTQLP
   601  GDAIYHISDL EEDEEEGITF QVQQPLEVEE KLSTSKPVTG IFLPPITSAG GPVTVATANP
   661  GKCLSCTNST FTFTTCRILH PSDITQVTPS SGFPSLSCGS SGSSSSNTAV NSPALSYRLS
   721  IGESITNRRD STTTFSSTMS LAKLLQERGI SAKVYHSPIS ENPLQPLPKS LAIPSTPPNS
   781  PSHSPCPSPL PFEPRVHLSE NFLASRPAET FLQEMYGLRP SRNPPDVGQL KMNLVDRLKR
   841  LGIARVVKNP GAQENGRCQE AEIGPQKPDS AVYLNSGSSL LGGLRRNQSL PVIMGSFAAP
   901  VCTSSPKMGV LKED

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TRAK2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.62
Highest tissue expression
196 nTPM

Expression across tissuesHPA

Tissue

  • spinal cord: 196 nTPM
  • midbrain: 78 nTPM
  • heart muscle: 66 nTPM
  • bone marrow: 49 nTPM
  • hippocampal formation: 43 nTPM
  • hypothalamus: 39 nTPM

Single-cell type

  • cardiomyocytes: 307 nCPM
  • melanocytes: 230 nCPM
  • somatotrophs: 215 nCPM
  • erythrocyte progenitors: 155 nCPM
  • retinal horizontal cells: 150 nCPM
  • adrenal cortex cells: 148 nCPM

Immune cell

  • naive B-cell: 14 nTPM
  • T-reg: 13 nTPM
  • NK-cell: 11 nTPM
  • memory CD4 T-cell: 10 nTPM
  • memory B-cell: 9.4 nTPM
  • gdT-cell: 7.8 nTPM

Brain region

  • spinal cord: 194 nTPM
  • white matter: 190 nTPM
  • medulla oblongata: 176 nTPM
  • pons: 151 nTPM
  • thalamus: 130 nTPM
  • midbrain: 121 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.82
gnomAD pLI
0
gnomAD missense Z
0.49
DepMap mean gene effect
0.03
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of TRAK2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TRAK2 as an antibody target. Whether an autoantibody or antibody against TRAK2 could matter depends on whether native TRAK2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TRAK2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label TRAK2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/TRAK2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...